{"id":"https://openalex.org/W3098537844","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0316","title":"316 EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A","display_name":"316 EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A","publication_year":2020,"publication_date":"2020-11-01","ids":{"openalex":"https://openalex.org/W3098537844","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0316","mag":"3098537844"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2020-sitc2020.0316","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0316","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0316","pdf_url":null,"source":{"id":"https://openalex.org/S4363604233","display_name":"Regular and Young Investigator Award Abstracts","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-paper","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0316","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065206480","display_name":"Aur\u00e9lien Marabelle","orcid":"https://orcid.org/0000-0002-5816-3019","observed_orcids":["https://orcid.org/0000-0002-5816-3019"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Aurelien Marabelle","raw_affiliation_strings":["Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089622240","display_name":"Christiane Jungels","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801838318","display_name":"Institut Jules Bordet","ror":"https://ror.org/05e8s8534","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2801838318"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Christiane Jungels","raw_affiliation_strings":["Institut Jules Bordet, Brussels, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Jules Bordet, Brussels, Belgium","institution_ids":["https://openalex.org/I2801838318"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072378199","display_name":"Johann Sebastian De Bono","orcid":"https://orcid.org/0000-0002-2034-595X","observed_orcids":["https://orcid.org/0000-0002-2034-595X"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Johann De Bono","raw_affiliation_strings":["The Institute for Cancer Research, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Institute for Cancer Research, London, UK","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053724616","display_name":"Norbert Vey","orcid":"https://orcid.org/0000-0001-7027-040X","observed_orcids":["https://orcid.org/0000-0001-7027-040X"]},"institutions":[{"id":"https://openalex.org/I4210150365","display_name":"Institut Paoli-Calmettes","ror":"https://ror.org/04s3t1g37","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4210150365"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Norbert Vey","raw_affiliation_strings":["Institut Paoli-Calmettes, Marseille, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Paoli-Calmettes, Marseille, France","institution_ids":["https://openalex.org/I4210150365"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034434819","display_name":"Martin Wermke","orcid":"https://orcid.org/0000-0002-4844-4087","observed_orcids":["https://orcid.org/0000-0002-4844-4087"]},"institutions":[{"id":"https://openalex.org/I4210162051","display_name":"University Hospital Carl Gustav Carus","ror":"https://ror.org/04za5zm41","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210162051"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Martin Wermke","raw_affiliation_strings":["Medical Faculty Carl Gustav Carus, Dresden, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Faculty Carl Gustav Carus, Dresden, Germany","institution_ids":["https://openalex.org/I4210162051"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059711568","display_name":"Elena Garralda","orcid":"https://orcid.org/0000-0002-4412-7842","observed_orcids":["https://orcid.org/0000-0002-4412-7842"]},"institutions":[{"id":"https://openalex.org/I4387155398","display_name":"Vall d'Hebron Institute of Oncology","ror":"https://ror.org/054xx3904","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4387153040","https://openalex.org/I4387155398"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Elena Garralda","raw_affiliation_strings":["Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain","institution_ids":["https://openalex.org/I4387155398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049504844","display_name":"Aude De Gassart","orcid":"https://orcid.org/0000-0002-0574-344X","observed_orcids":["https://orcid.org/0000-0002-0574-344X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aude de Gassart","raw_affiliation_strings":["ImCheck Therapeutics, Marseille, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImCheck Therapeutics, Marseille, France","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088708457","display_name":"Patrick Brune","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Patrick Brune","raw_affiliation_strings":["ImCheck Therapeutics, Marseille, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImCheck Therapeutics, Marseille, France","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014777472","display_name":"Emmanuel Di Valentin","orcid":"https://orcid.org/0000-0002-5287-7950","observed_orcids":["https://orcid.org/0000-0002-5287-7950","https://orcid.org/0000-0002-5313-2547"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Emmanuel Valentin","raw_affiliation_strings":["ImCheck Therapeutics, Marseille, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImCheck Therapeutics, Marseille, France","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029856675","display_name":"Marina Ich\u00e9","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marina Ich\u00e9","raw_affiliation_strings":["ILife Consulting, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ILife Consulting, Paris, France","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029679351","display_name":"Daniel Olive","orcid":"https://orcid.org/0000-0003-1299-4113","observed_orcids":["https://orcid.org/0000-0003-1299-4113"]},"institutions":[{"id":"https://openalex.org/I4210144608","display_name":"Centre de Recherche en Canc\u00e9rologie de Marseille","ror":"https://ror.org/0494jpz02","country_code":"FR","type":"facility","lineage":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I21491767","https://openalex.org/I4210096427","https://openalex.org/I4210144608","https://openalex.org/I4210150365"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Daniel Olive","raw_affiliation_strings":["Centre de recherche en Canc\u00e9rologie, Marseille, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre de recherche en Canc\u00e9rologie, Marseille, France","institution_ids":["https://openalex.org/I4210144608"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5007313865","display_name":"Paul Frohna","orcid":"https://orcid.org/0000-0002-2251-2686","observed_orcids":["https://orcid.org/0000-0002-2251-2686"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul Frohna","raw_affiliation_strings":["ImCheck Therapeutics, Marseille, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImCheck Therapeutics, Marseille, France","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.6963,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":{"value":0.92370414,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":97},"biblio":{"volume":null,"issue":null,"first_page":"A194","last_page":"A195"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.00839999970048666,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.005200000014156103,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/btn3a","display_name":"BTN3A","score":0.8870000243186951},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.531000018119812},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.7459999918937683},{"id":"https://openalex.org/keywords/pembrolizumab-combination","display_name":"pembrolizumab combination","score":0.8240000009536743},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.5329999923706055},{"id":"https://openalex.org/keywords/cytokine-response","display_name":"cytokine response","score":0.5220000147819519},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.593999981880188},{"id":"https://openalex.org/keywords/relapsed-refractory-cancer","display_name":"relapsed/refractory cancer","score":0.7739999890327454},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.8360000252723694},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.6480000019073486},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.7910000085830688},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":0.9179999828338623}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.6973088383674622},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5084530115127563},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.49109458923339844},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.46791842579841614},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4641481637954712},{"id":"https://openalex.org/C196166836","wikidata":"https://www.wikidata.org/wiki/Q902926","display_name":"Immunophenotyping","level":3,"score":0.4564204216003418},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.44941505789756775},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4163919687271118},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.332882821559906},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.31775861978530884},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.258412629365921},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.18591025471687317}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1136/jitc-2020-sitc2020.0316","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0316","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0316","pdf_url":null,"source":{"id":"https://openalex.org/S4363604233","display_name":"Regular and Young Investigator Award Abstracts","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},{"id":"pmh:oai:doaj.org/article:67dfe215c30340c798d8e73e64278d3c","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/67dfe215c30340c798d8e73e64278d3c","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2020-sitc2020.0316","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0316","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0316","pdf_url":null,"source":{"id":"https://openalex.org/S4363604233","display_name":"Regular and Young Investigator Award Abstracts","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.6100000143051147}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3182143239","https://openalex.org/W4308399096","https://openalex.org/W3212868972","https://openalex.org/W4282966202","https://openalex.org/W4365512150","https://openalex.org/W4387826008","https://openalex.org/W4400272318","https://openalex.org/W3204953812","https://openalex.org/W4388047712","https://openalex.org/W3206960301"],"abstract_inverted_index":{"Background":[0],"Gamma9":[1],"Delta2":[2],"(\u03b39\u03b42)":[3],"T":[4,30,54,67,104,237,288,336,343,361,376,422],"cells":[5,31,68,238,289,344,423],"are":[6,44,223,395],"an":[7,32,475],"important":[8],"component":[9],"of":[10,39,47,65,77,87,98,110,139,142,242,333,420,496,505,516],"the":[11,36,74,83,108,134,164,178,331,391,411,416,442,492,506,514],"innate":[12,417],"anti-tumor":[13,243,418],"immune":[14,48],"response":[15],"whose":[16],"infiltration":[17],"into":[18],"solid":[19,113,252],"tumors":[20,253],"has":[21,262,410],"been":[22,263,283],"associated":[23],"with":[24,112,149,153,201,251,267],"a":[25,45,61,89,126,322],"positive":[26],"prognosis,":[27],"making":[28],"\u03b39\u03b42":[29,53,66,103,236,335,342,375,421],"attractive":[33],"target":[34],"for":[35,107,208,234,494,511],"next":[37],"generation":[38],"cancer":[40,170],"immunotherapy.":[41],"Butyrophilins":[42],"(BTNs)":[43],"family":[46],"checkpoint":[49],"molecules":[50],"that":[51,59,93,408],"regulate":[52],"cell":[55,105],"activity,":[56],"including":[57],"BTN3A":[58],"is":[60,125,166,509],"potent":[62],"endogenous":[63],"activator":[64],"following":[69,443],"phosphoantigen":[70],"(pAg)":[71],"binding":[72],"to":[73,82,132,186,195,273,413],"intracellular":[75],"domain":[76],"BTN3A1.":[78],"This":[79,437],"observation":[80],"led":[81],"design":[84],"and":[85,100,137,146,160,177,210,227,230,239,265,307,325,350,399,499],"development":[86],"ICT01,":[88],"humanized,":[90],"monoclonal":[91],"antibody":[92],"binds":[94],"all":[95],"3":[96,199],"isoforms":[97],"BTN3A1/A2/A3":[99],"induces":[101],"pAg-independent":[102],"activation,":[106],"treatment":[109],"patients":[111,152,189,250],"or":[114,279,359,365],"hematologic":[115],"tumors.":[116],"Methods":[117],"EVICTION":[118],"(www.":[119],"clinicaltrials.gov":[120],"NCT04243499;":[121,431],"EudraCT":[122,432],"Number:":[123,433],"2019-003847-31)":[124],"first-in-human,":[127],"two-part,":[128],"open-label,":[129],"clinical":[130],"study":[131,165,438],"assess":[133],"safety,":[135],"tolerability":[136],"activity":[138],"intravenous":[140],"doses":[141,269],"ICT01":[143,191,268,409],"as":[144],"monotherapy":[145],"in":[147,151,172,330,370,380],"combination":[148],"pembrolizumab,":[150],"advanced-stage,":[154],"relapsed/refractory":[155],"cancer.":[156],"Following":[157],"Competent":[158],"Authority":[159],"Ethics":[161,435,444,483],"Committee":[162],"approvals,":[163],"being":[167,397],"conducted":[168],"at":[169,205,225,290,298,303,309,316],"centers":[171],"France,":[173],"Belgium,":[174],"Spain,":[175],"Germany,":[176],"UK.":[179],"Patients":[180],"provide":[181],"signed":[182],"informed":[183,487],"consent":[184,488,508],"prior":[185],"screening.":[187],"Eligible":[188],"receive":[190],"(Range:":[192],"20":[193,272],"\u00b5g":[194,300,305,311],"200":[196,304],"mg)":[197],"every":[198],"weeks":[200],"blood":[202],"samples":[203],"collected":[204,224],"multiple":[206],"timepoints":[207],"immunophenotyping":[209],"cytokine":[211,384],"analysis":[212],"(IFN\u03b3,":[213],"IL-1\u03b2,":[214],"IL-2,":[215],"IL-4,":[216],"IL-6,":[217],"IL-8,":[218],"IL-13,":[219],"TNF\u03b1).":[220],"Tumor":[221],"biopsies":[222,394],"baseline":[226,329],"Day":[228,340],"28":[229],"stained":[231],"by":[232,321,347,373,441,513],"immunohistochemistry":[233],"BTN3A,":[235],"other":[240],"markers":[241],"immunity.":[244],"Results":[245],"Cohort":[246],"1":[247,256,258,260],"comprising":[248],"6":[249],"(3":[254],"Colorectal,":[255],"Pancreatic,":[257],"Ovarian,":[259],"Melanoma)":[261],"enrolled":[264],"treated":[266],"ranging":[270],"from":[271,328,390,491],"700":[274,310],"\u00b5g.":[275],"No":[276,383],"dose-limiting":[277],"toxicities":[278],"related":[280],"SAEs":[281],"have":[282],"reported.":[284],"Target":[285],"occupancy":[286],"on":[287,357],"4":[291],"hours":[292,318],"post":[293,319],"first":[294],"dose":[295,320],"was":[296,314,387,439,489],"10%":[297],"70":[299],"(n=1),":[301],"31%":[302],"(n=2)":[306],"34%":[308],"(n=2),":[312],"which":[313],"reflected":[315],"24":[317],"73%,":[323],"91%":[324],"97%":[326],"decrease":[327],"number":[332],"circulating":[334],"cells,":[337,362,364,377],"respectively.":[338,352],"On":[339],"7,":[341],"remained":[345],"decreased":[346],"37%,":[348],"75%":[349],"76%,":[351],"There":[353],"were":[354,378],"no":[355],"effects":[356],"CD4":[358],"CD8":[360],"NK":[363],"B":[366],"cells.":[367],"Transient":[368],"increases":[369],"IFN\u03b3,":[371],"secreted":[372],"activated":[374],"observed":[379],"4/6":[381],"patients.":[382],"release":[385],"syndrome":[386],"observed.":[388],"Data":[389],"paired":[392],"tumor":[393],"still":[396],"generated":[398],"will":[400],"be":[401],"presented.":[402],"Conclusions":[403],"The":[404],"preliminary":[405],"results":[406],"demonstrate":[407],"potential":[412,419],"safely":[414],"activate":[415],"through":[424],"BTN3A.":[425],"Acknowledgements":[426],".":[427],"Trial":[428],"Registration":[429],"www.clinicaltrials.gov":[430],"2019-003847-31":[434],"Approval":[436],"approved":[440],"Committees:":[445],"COMITE":[446],"DE":[447,462,464],"PROTECTION":[448],"DES":[449],"PERSONNES,":[450],"Sud-M\u00e9diterran\u00e9e":[451],"V":[452],"(Gustave":[453],"Roussy,":[454],"IPC),":[455],"Comit\u00e9":[456],"d\u2019Ethique":[457],"Institut":[458],"Jules":[459],"Bordet,":[460],"COMIT\u00c9":[461],"\u00c9TICA":[463],"INVESTIGACI\u00d3N":[465],"CL\u00cdNICA":[466],"CON":[467],"MEDICAMENTOS":[468],"del":[469],"Hospital":[470],"Universitari":[471],"Vall":[472],"d\u2019Hebron,":[473],"Ethikkommission":[474],"der":[476],"TU":[477],"Dresden,":[478],"HRA":[479],"London-Surrey":[480],"Borders":[481],"Research":[482],"Committee.":[484],"Consent":[485],"Written":[486],"obtained":[490],"patient":[493],"publication":[495],"this":[497,517],"abstract":[498],"any":[500],"accompanying":[501],"images.":[502],"A":[503],"copy":[504],"written":[507],"available":[510],"review":[512],"Editor":[515],"journal.":[518]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":4}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2020-11-23T00:00:00"}